217 related articles for article (PubMed ID: 20337650)
1. Reproducibility of nasal allergen challenge in evaluating the efficacy of intranasal corticosteroid treatment.
Proud D; Riker DK; Togias A
Clin Exp Allergy; 2010 May; 40(5):738-44. PubMed ID: 20337650
[TBL] [Abstract][Full Text] [Related]
2. Nasal challenge with allergen leads to maxillary sinus inflammation.
Baroody FM; Mucha SM; Detineo M; Naclerio RM
J Allergy Clin Immunol; 2008 May; 121(5):1126-1132.e7. PubMed ID: 18367240
[TBL] [Abstract][Full Text] [Related]
3. Effects of intranasal azelastine on the response to nasal allergen challenge.
Saengpanich S; Assanasen P; deTineo M; Haney L; Naclerio RM; Baroody FM
Laryngoscope; 2002 Jan; 112(1):47-52. PubMed ID: 11802037
[TBL] [Abstract][Full Text] [Related]
4. Low dose clemastine inhibits sneezing and rhinorrhea during the early nasal allergic reaction.
Chung JH; deTineo ML; Naclerio RM; Sorrentino JV; Winslow CM; Baroody FM
Ann Allergy Asthma Immunol; 1997 Mar; 78(3):307-12. PubMed ID: 9087158
[TBL] [Abstract][Full Text] [Related]
5. Intranasal beclomethasone reduces allergen-induced symptoms and superficial mucosal eosinophilia without affecting submucosal inflammation.
Baroody FM; Rouadi P; Driscoll PV; Bochner BS; Naclerio RM
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):899-906. PubMed ID: 9517609
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages.
Gosset P; Tillie-Leblond I; Malaquin F; Durieu J; Wallaert B; Tonnel AB
Clin Exp Allergy; 1997 Apr; 27(4):379-88. PubMed ID: 9146930
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
Korsgren M; Andersson M; Borgå O; Larsson L; Aldén-Raboisson M; Malmqvist U; Greiff L
Ann Allergy Asthma Immunol; 2007 Apr; 98(4):316-21. PubMed ID: 17458426
[TBL] [Abstract][Full Text] [Related]
9. Effects of fexofenadine on the early response to nasal allergen challenge.
Allocco FT; Votypka V; deTineo M; Naclerio RM; Baroody FM
Ann Allergy Asthma Immunol; 2002 Dec; 89(6):578-84. PubMed ID: 12487223
[TBL] [Abstract][Full Text] [Related]
10. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis.
Ahlström-Emanuelsson C; Andersson M; Persson C; Schrewelius C; Greiff L
Clin Exp Allergy; 2004 May; 34(5):731-5. PubMed ID: 15144464
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model.
Andersson M; Svensson C; Persson C; Akerlund A; Greiff L
Ann Allergy Asthma Immunol; 2000 Oct; 85(4):279-83. PubMed ID: 11061470
[TBL] [Abstract][Full Text] [Related]
12. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
Krug N; Hohlfeld JM; Geldmacher H; Larbig M; Heermann R; Lavallee N; Nguyen DT; Petzold U; Hermann R
Allergy; 2005 Mar; 60(3):354-9. PubMed ID: 15679722
[TBL] [Abstract][Full Text] [Related]
13. Nasal treatment with a microemulsion reduces allergen challenge-induced symptoms and signs of allergic rhinitis.
Andersson M; Greiff L; Wollmer P
Acta Otolaryngol; 2008 Jun; 128(6):666-9. PubMed ID: 18568502
[TBL] [Abstract][Full Text] [Related]
14. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge.
Erin EM; Zacharasiewicz AS; Nicholson GC; Tan AJ; Higgins LA; Williams TJ; Murdoch RD; Durham SR; Barnes PJ; Hansel TT
Clin Exp Allergy; 2005 Dec; 35(12):1608-14. PubMed ID: 16393327
[TBL] [Abstract][Full Text] [Related]
15. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge.
Ciprandi G; Tosca MA; Passalacqua G; Canonica GW
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):433-8. PubMed ID: 11345288
[TBL] [Abstract][Full Text] [Related]
16. Important roles of tachykinins in the development of allergic nasal hyperresponsiveness in guinea-pigs.
Nabe T; Tsuzuike N; Ohtani Y; Mizutani N; Watanabe S; Fujii M; Yoshimura M; Nagasawa M; Kohno S
Clin Exp Allergy; 2009 Jan; 39(1):138-46. PubMed ID: 18778270
[TBL] [Abstract][Full Text] [Related]
17. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis.
Weido AJ; Reece LM; Alam R; Cook CK; Sim TC
Ann Allergy Asthma Immunol; 1996 Nov; 77(5):407-15. PubMed ID: 8933780
[TBL] [Abstract][Full Text] [Related]
18. Applicability and reproducibility of biomarkers for the evaluation of anti-inflammatory therapy in allergic rhinitis.
Boot JD; Chandoesing P; de Kam ML; Mascelli MA; Das AM; Gerth van Wijk R; de Groot H; Verhoosel R; Hiemstra PS; Diamant Z
J Investig Allergol Clin Immunol; 2008; 18(6):433-42. PubMed ID: 19123434
[TBL] [Abstract][Full Text] [Related]
19. Nasal immunotherapy in weed-induced allergic rhinitis.
Gaglani B; Borish L; Bartelson BL; Buchmeier A; Keller L; Nelson HS
Ann Allergy Asthma Immunol; 1997 Sep; 79(3):259-65. PubMed ID: 9305235
[TBL] [Abstract][Full Text] [Related]
20. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study.
Rimmer J; Peake HL; Santos CM; Lean M; Bardin P; Robson R; Haumann B; Loehrer F; Handel ML
Clin Exp Allergy; 2007 Jan; 37(1):8-14. PubMed ID: 17210036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
